MR. AHMED DANIYAAL RASHEED M.D.
Prescription History 1174197313
Student in an Organized Health Care Education/Training Program in Washington, DC

NPI Status: Active since May 13, 2021

Contact Information

110 IRVING STREET NW
MEDSTAR WASHINGTON HOSPITAL CENTER
WASHINGTON, DC
ZIP 20010
Phone: (202) 877-2835

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MR. AHMED DANIYAAL RASHEED M.D., an active Student in an Organized Health Care Education/Training Program specialist practicing in Washington, DC. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 46 documented patient claims. Among these therapy options, the most frequently utilized medication is Atorvastatin Calcium, which accounts for 20 claims alone.

Medication Index

No matching medications currently found on file.

Atorvastatin Calcium

Generic Formulation: Atorvastatin CalciumSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 20
30-Day Fills 34.0
Days Supply 1,020
DC State Average Benchmarks
Peer Average Claims102.0
Peer Average 30-Day Fills248.3
Peer Average Days Supply7,332
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 80.4% less volume than the regional standard for practitioners inside DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $177.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.89

State Avg Cost Per Claim

$14.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrole and heptanoic acid derivative, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR (statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL; APOLIPOPROTEIN B; and TRIGLYCERIDES. It is used to increase serum levels of HDL-CHOLESTEROL in the treatment of HYPERLIPIDEMIAS, and for the prevention of CARDIOVASCULAR DISEASES in patients with multiple risk factors.

Therapeutic Applications

Atorvastatin is used along with a proper diet to help lower bad cholesterol and fats (such as LDL, triglycerides) and raise good cholesterol (HDL) in the blood. It belongs to a group of drugs known as statins. It works by reducing the amount of cholesterol made by the liver. Lowering bad cholesterol and triglycerides and raising good cholesterol decreases the risk of heart disease and helps prevent strokes and heart attacks. In addition to eating a proper diet (such as a low-cholesterol/low-fat diet), other lifestyle changes that may help this medication work better include exercising, losing weight if overweight, and stopping smoking. Consult your doctor for more details.

Finasteride

Generic Formulation: FinasterideSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
DC State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills113.4
Peer Average Days Supply3,352
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.1% less volume than the regional standard for practitioners inside DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $134.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.35

State Avg Cost Per Claim

$18.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.

Therapeutic Applications

Finasteride is used to shrink an enlarged prostate (benign prostatic hyperplasia or BPH) in adult men. It may be used alone or taken in combination with other medications to reduce symptoms of BPH and may also reduce the need for surgery. Finasteride may improve symptoms of BPH and provide benefits such as decreased urge to urinate, better urine flow with less straining, less of a feeling that the bladder is not completely emptied, and decreased nighttime urination. This medication works by decreasing the amount of a natural body hormone (DHT) that causes growth of the prostate. Finasteride is not approved for prevention of prostate cancer. It may slightly increase the risk of developing a very serious form of prostate cancer. Talk to your doctor about the benefits and risks. Women and children should not use this medication.

Gabapentin

Generic Formulation: GabapentinSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
DC State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills72.6
Peer Average Days Supply2,095
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.7% less volume than the regional standard for practitioners inside DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $156.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.00

State Avg Cost Per Claim

$22.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MR. AHMED DANIYAAL RASHEED M.D. provides transparency into local medical care patterns within Washington, DC.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Student in an Organized Health Care Education/Training Program** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.